BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk...

Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

July 19 2018 Cochrane researchers have published research indicating that omega 3 supplements...

DOACs associated with reduced risk of major bleeding compared to warfarin

DOACs associated with reduced risk of major bleeding compared to warfarin

July 11 2018 Direct oral anticoagulants (DOACs) have been associated with reduced risks of major...

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

July 3 2018 People who have a record of penicillin allergy are at an increased risk of developing...

MPS advises of need for better awareness of cauda equina red flag symptoms

MPS advises of need for better awareness of cauda equina red flag symptoms

May 9 2018 The Medical Protection Society is advising doctors of a revision to the NICE Clinical...

  • BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    Wednesday, 25 July 2018 14:07
  • Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

    Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

    Thursday, 19 July 2018 10:36
  • DOACs associated with reduced risk of major bleeding compared to warfarin

    DOACs associated with reduced risk of major bleeding compared to warfarin

    Wednesday, 11 July 2018 13:22
  • Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Tuesday, 03 July 2018 16:51
  • MPS advises of need for better awareness of cauda equina red flag symptoms

    MPS advises of need for better awareness of cauda equina red flag symptoms

    Wednesday, 09 May 2018 16:01

smclogoJuly 22 2015

The Scottish Medicines Consortium has published its latest recommendations for medicines used in the NHS in Scotland.

Its July Briefing Note lists five medicines recommended for use as follows:

  • vedolizumab (Entyvio) is recommended for restricted use in adults with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to a tumour necrosis factor-alpha (TNFα) antagonist;
  • ceftobiprole (Zevtera) is recommended for restricted use in adults for hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), for certain organisms;
  • riociguat (Adempas) is recommended for restricted use in adults with pulmonary arterial hypertension (PAH) with World Health Organization Functional Class (WHO FC) II to III PAH as an alternative treatment option to endothelin receptor antagonist (ERA) monotherapy;
  • sorafenib (Nexavar) is accepted for use as a chemotherapeutic agent in progressive, locally advanced or metastatic, differentiated thyroid carcinoma which is refractory to radioactive iodine;
  • tinzaparin (Innohep) is accepted for use as a chemotherapeutic agent in patients with solid tumours for the extended treatment of symptomatic venous thrombo-embolism (VTE) and prevention of its recurrence.

Three medicines are currently not recommended for NHS use:

  • rivaroxaban (Xarelto) is not recommended for use co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome with elevated cardiac biomarkers;
  • olaparib (Lynparza) is not recommended for use in advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer;
  • vinflunine (Javlor) is not recommended for use in locally advanced or metastatic transitional cell carcinoma of the urothelial tract (TCCU).

In Wales, the All Wales Medicines Strategy Group has made the following recommendations in favour of using medicines within NHS Wales:

  • levonorgestrel (Jaydess) as an option for use for contraception for up to three years;
  • darunavir (Prezista) co-administered with low dose ritonavir in combination with other antiretroviral medicinal products as an option for HIV-1 infection in children aged three years or over and weighing at least 15kg;
  • avanafil (Spedra) as an option for the treatment of erectile dysfunction in adult men;
  • peginterferon beta-1a (Plegridy) as an option for treating relapsing remitting multiple sclerosis;
  • regorafenib (Stivarga) for use in adults with unresectable or metastatic gastrointestinal stromal tumours (GIST) under certain circumstances.

Links:

Scottish Medicines Consortium Briefing Note July 2015    

All Wales Medicines Strategy Group recommendations

Clinical News

July 27 2018 Adolescent boys will be offered the human papilloma virus (HPV) vaccine to protect them from cancer, the Department of Health and Social Care has announced.
July 20 2018 Doctors are being reminded to ensure that any patient or other records which may be relevant to the UK Infected Blood Inquiry are not destroyed. Earlier this month, the Inquiry’s Chair, Sir...